公开(公告)号：US10800793B2

公开(公告)日：2020-10-13

申请号：US16141856

申请日：2018-09-25

Applicant: NOVARTIS AG

Inventor： Simone Bonazzi ,  Michael Connolly ,  David Jonathan Glass ,  Manuel Mihalic ,  Andrew William Patterson ,  Silvio Roggo ,  Tea Shavlakadze

IPC: C07D498/18 ,  A61P35/00 ,  A61P13/12 ,  A61P1/16 ,  A61P25/16 ,  A61P37/00 ,  A61P9/10 ,  A61P19/10 ,  A61P19/00 ,  A61P29/00 ,  A61P31/10 ,  A61P19/02 ,  A61P25/28 ,  A61P3/10 ,  A61P9/12 ,  A61P11/00 ,  A61P3/04 ,  C07F9/6561 ,  A61P25/02

Abstract: The disclosure relates to compounds of formula (I) and pharmaceutically acceptable salts, and compositions thereof, wherein the substituents are as defined herein. Also provided are methods of making compounds of formula (I), and methods involving the compounds or compositions for treating disorders and diseases described herein.

公开(公告)号：US20200215171A1

公开(公告)日：2020-07-09

申请号：US16728557

申请日：2019-12-27

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Hilmar Erhard Ebersbach ,  Saar Gill ,  David Jonathan Glass ,  Julia Jascur ,  Saad Kenderian ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  Celeste Richardson ,  Reshma Singh ,  Lai Wei ,  Qilong Wu ,  Qiumei Yang ,  Jiquan Zhang

IPC: A61K39/00 ,  C07K14/725 ,  C07K16/28 ,  A61K35/17 ,  A61K31/7068 ,  A61K45/06 ,  C07K14/705

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.

公开(公告)号：US10703819B2

公开(公告)日：2020-07-07

申请号：US15726703

申请日：2017-10-06

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Saar Gill ,  David Jonathan Glass ,  Saad Kenderian ,  Andreas Loew ,  Joan Mannick ,  Michael Milone ,  Leon Murphy ,  David L. Porter ,  Marco Ruella ,  Yongqiang Wang ,  Qilong Wu ,  Jiquan Zhang

IPC: C07K16/28 ,  A61K39/00 ,  C07K16/24 ,  C12N5/0783

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.

公开(公告)号：US12281125B2

公开(公告)日：2025-04-22

申请号：US17414696

申请日：2019-12-17

Applicant: NOVARTIS AG

Inventor： Simone Bonazzi ,  Michael Connolly ,  David Jonathan Glass ,  Manuel Mihalic ,  Andrew W. Patterson ,  Silvio Roggo ,  Tea Shavlakadze ,  Patrik Zueger

IPC: C07D498/18 ,  A61K31/436 ,  A61K45/06

Abstract: The disclosure provides 32-deoxo-rapamycin derivatives of Formula (I), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions and pharmaceutical combinations comprising a compound of Formula (I), and methods of making same. Also provided herein are methods of using a compound of Formula (I) or a pharmaceutically acceptable salt thereof for treating the diseases and disorders described herein.

公开(公告)号：US12214037B2

公开(公告)日：2025-02-04

申请号：US17359211

申请日：2021-06-25

Applicant: The Trustees of the University of Pennsylvania ,  Novartis AG

Inventor： Jennifer Brogdon ,  Eugene Choi ,  Hilmar Erhard Ebersbach ,  David Jonathan Glass ,  Heather Huet ,  Carl H. June ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  Gabriela Plesa ,  Celeste Richardson ,  Marco Ruella ,  Reshma Singh ,  Yongqiang Wang ,  Qilong Wu

IPC: A61K39/00 ,  A61K39/395 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  A61K35/12 ,  A61K38/17 ,  A61P35/00 ,  C07H21/04 ,  C07K14/715 ,  C07K19/00 ,  C12N5/00 ,  C12N15/63

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

公开(公告)号：US11578130B2

公开(公告)日：2023-02-14

申请号：US16210480

申请日：2018-12-05

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Boris Engels ,  David Jonathan Glass ,  Brian Granda ,  John Hastewell ,  Andreas Loew ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  William Raj Sellers ,  Huijuan Song ,  Brian Edward Vash ,  Jan Weiler ,  Qilong Wu ,  Li Zhou

IPC: C07K16/28 ,  A61K31/436 ,  A61K35/17 ,  C07K14/705 ,  C07K14/71 ,  C07K14/725 ,  C07K14/74 ,  C12N9/12 ,  C12N9/90

Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

公开(公告)号：US20220202787A1

公开(公告)日：2022-06-30

申请号：US17442733

申请日：2020-03-25

Applicant: NOVARTIS AG

Inventor： Simone Bonazzi ,  Michael Connolly ,  David Jonathan Glass ,  Andrew W. Patterson ,  Tea Shavlakadze

IPC: A61K31/439 ,  A61K45/06 ,  C07D498/18

Abstract: Described herein are compounds of Formula (I) that are inhibitors of mTORC1, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

公开(公告)号：US11084880B2

公开(公告)日：2021-08-10

申请号：US16197565

申请日：2018-11-21

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Eugene Choi ,  Hilmar Erhard Ebersbach ,  David Jonathan Glass ,  Heather Huet ,  Carl H. June ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  Gabriela Plesa ,  Celeste Richardson ,  Marco Ruella ,  Reshma Singh ,  Yongqiang Wang ,  Qilong Wu

IPC: C07K16/28 ,  C07K14/705 ,  C07K19/00 ,  C07K14/725 ,  A61P35/00 ,  A61K39/395 ,  A61K35/12 ,  A61K38/17 ,  C07K14/715 ,  C07H21/04 ,  C12N15/63 ,  C12N5/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

公开(公告)号：US20210002377A1

公开(公告)日：2021-01-07

申请号：US16884867

申请日：2020-05-27

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Saar Gill ,  David Jonathan Glass ,  Saad Kenderian ,  Andreas Loew ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  David L. Porter ,  Marco Ruella ,  Yongqiang Wang ,  Qilong Wu ,  Jiquan Zhang

IPC: C07K16/28 ,  A61K39/00 ,  C07K16/24 ,  C12N5/0783

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.

公开(公告)号：US20200339651A1

公开(公告)日：2020-10-29

申请号：US16708397

申请日：2019-12-09

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Gregory Beatty ,  David Jonathan Glass ,  Carl H. June ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  Gabriela Plesa ,  Huijuan Song ,  Qilong Wu

IPC: C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  A61K31/436 ,  A61K31/675 ,  A61K35/17 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  A61N5/10

Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to the methods of preconditioning a subject, e.g., by depleting B cells in combination with the use of a cell comprising a chimeric antigen receptor (CAR) that targets a tumor antigen as described herein. The methods for preconditioning the subject described herein include using a cell comprising a CAR that targets a B cell antigen as described herein.